title: Failure of metoclopramide to control emesis or nausea due to stressful angular or linear acceleration.
abstract: Orally administered metoclopramide (REGLAN) at doses of 10 or 20 mg, 75 min prior to either stressful linear acceleration (parabolic flight) or cross-coupled accelerative semicircular canal stimulation in a rotating chair was evaluated for its ability to prevent emesis or nausea II, respectively. Although metoclopramide is an effective antiemetic agent that enhances gastric emptying and prevents cancer chemotherapy-induced emesis, we were unable to demonstrate any significant (p less than 0.05) effects of this drug on motion sickness.
mesh_terms: D000054:Acceleration / Q000009:adverse effects*; D000328:Adult; D003312:Coriolis Force; D006801:Humans; D008787:Metoclopramide / Q000627:therapeutic use*; D009041:Motion Sickness / Q000188:drug therapy* / Q000209:etiology; D009325:Nausea / Q000188:drug therapy* / Q000209:etiology; D013026:Space Flight
chemical_list: D008787:Metoclopramide